---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-25-000149"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:59:05.743721+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M

## Summary
- Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.
- Phase 1 trial of PLN-101095 in solid tumors ongoing; data from top two dose cohorts expected by end of 2025.
- Workforce restructuring largely complete; cash, cash equivalents and short-term investments at $264.4M as of June 30.
- Q2 R&D expenses fell to $32.2M from $45.6M; G&A dropped to $13.4M from $15.0M.
- Net loss of $43.3M improved from $55.9M in prior-year quarter, driven by restructuring and trial discontinuation.

## SEC filing metadata
- accession: 0001746473-25-000149
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/0001746473-25-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/plrx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-25-000149
- JSON: https://secwatch.observer/filing/0001746473-25-000149.json
- Plain text: https://secwatch.observer/filing/0001746473-25-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.